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Abstract
Background: TPC-1 is a papillary thyroid carcinoma (PTC)-derived cell line that spontaneously expresses the
oncogene RET/PTC1. TPC-1 treated with the RET/PTC1 inhibitor RPI-1 displayed a cytostatic and reversible inhibition
of cell proliferation and a strong activation of focal adhesion kinase (FAK). As dasatinib inhibition of Src results in
reduction of FAK activation, we evaluated the effects of TPC-1 treatment with dasatinib in combination with RPI-1.
Results: Dasatinib (100 nM) strongly reduced TPC-1 proliferation and induced marked changes in TPC-1
morphology. Cells appeared smaller and more contracted, with decreased cell spreading, due to the inhibition of
phosphorylation of important cytoskeletal proteins (p130
CAS, Crk, and paxillin) by dasatinib. The combination of RPI-
1 with dasatinib demonstrated enhanced effects on cell proliferation (more than 80% reduction) and on the
phosphotyrosine protein profile. In particular, RPI-1 reduced the phosphorylation of RET, MET, DCDB2, CTND1, and
PLCg, while dasatinib acted on the phosphorylation of EGFR, EPHA2, and DOK1. Moreover, dasatinib completely
abrogated the phosphorylation of FAK at all tyrosine sites (Y576, Y577, Y861, Y925) with the exception of the
autoactivation site (Y397). Notably, the pharmacological treatments induced an overexpression of integrin b1 (ITB1)
that was correlated with a mild enhancement in phosphorylation of ERK1/2 and STAT3, known for their roles in
prevention of apoptosis and in increase of proliferation and survival. A reduction in Akt, p38 and JNK1/2 activation
was observed.
Conclusions: All data demonstrate that the combination of the two drugs effectively reduced cell proliferation (by
more than 80%), significantly decreased Tyr phosphorylation of almost all phosphorylable proteins, and altered the
morphology of the cells, supporting high cytostatic effects. Following the combined treatment, cell survival
pathways appeared to be mediated by STAT3 and ERK activities resulting from integrin clustering and FAK
autophosphorylation. EphA2 may also contribute, at least in part, to integrin and FAK activation. In conclusion,
these data implicate ITB1 and EphA2 as promising therapeutic targets in PTC.
Background
The transformation of normal follicular thyroid cells
into cancer cells is a multistep process involving genetic
alterations associated with aberrant growth control, loss
of differentiation, and invasiveness [1]. Thyroid carcino-
mas can be divided into four groups: papillary, follicular,
medullary, and anaplastic carcinomas [2]. Papillary thyr-
oid carcinoma (PTC) is the most prevalent of these can-
cer subtypes. PTC is associated with characteristic
genetic alterations that include rearrangement of the
tyrosine kinase receptor oncogenes RET and NTRK1
and point mutations in the Ras and BRAF genes [3,4].
Specific rearranged forms of RET were detected in PTC
that are the result of double-stranded DNA breaks
(mostly radiation-induced), leading to the erroneous
reparative fusion of the 3’ portion of RET to the 5’ por-
tion of a constitutively-expressed unrelated gene and
producing RET/PTC genes [5]. Approximately 17 differ-
ent hybrid oncogenes have been reported; the most pre-
valent variants are RET/PTC1 (the H4-RET fusion) and
RET/PTC3 (the RFG-RET fusion), accounting for > 90%
of all known rearrangements [6,7].
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low molecular weight are being tested and used in clini-
cal practice as anticancer agents [8]. For instance,
PLX4032 is a highly-selective inhibitor of BRAF kinase
activity with an IC50 of 44 nmol/l against the BRAF
V600E
mutant [9], while RPI-1 is a selective inhibitor of RET
kinase activity [10]. Specifically, RPI-1 is an orally-avail-
able, indolinone-based tyrosine kinase inhibitor, initially
described as an inhibitor of the fusion protein RET/
PTC1. RPI-1 showed high effectiveness in controlling
the growth of thyroid tumors by inhibiting tyrosine
kinase activity, expression, and signaling of RET in TT
cell line [11]. Moreover, treatment with RPI-1 inhibited
the proliferation of the TPC-1 cell line, which harbors
the RET/PTC1 rearrangement, and induced accumula-
tion of these cells at the G2 cell cycle phase. In treated
cells, RET/PTC1 tyrosine phosphorylation was abolished
along with its binding to Shc and phospholipase C,
abrogating constitutive signaling mediated by the onco-
protein. Like many other inhibitors, RPI-1 causes a cyto-
static and reversible inhibition of cell proliferation [12].
We have previously reported that thyroid tumor cell
lines expressing RET oncoproteins after RPI-1 treatment
maintained strong activation of focal adhesion kinase
(FAK), one of the most prominent phosphorylated pro-
teins in the PTC cell line TPC-1 [13]. FAK is a non-
receptor tyrosine kinase that localizes at focal adhesions
and is activated by integrin clustering or by growth fac-
tor receptor activation. FAK presents six phosphoryla-
tion sites that are differentially phosphorylated in
response to various stimuli. After autophosphorylation
at Y397, FAK becomes activated and can recruit other
proteins. The binding of Src leads to the full activation
of FAK through the Src-mediated phosphorylation of
Y576 and Y577 in the FAK activation loop [14].
Src family kinases (SFKs) represent the largest family of
non-receptor tyrosine kinases that interact directly with
receptor tyrosine kinases, signal transducers, activators of
transcription, and molecules involved in cell adhesion
and migration. Aberrant expression or activation of SFKs
causes perturbations in these activities, leading to trans-
formation and progression of malignant disease [15].
Moreover, Src activity contributes to the growth and sur-
vival of malignant cancers such as breast, prostate, and
lung, implicating this kinase as a promising therapeutic
target for a wide range of human cancers [16,17].
Dasatinib is an ATP-competitive tyrosine kinase inhi-
bitor that inhibits all SFKs at low concentrations (IC50 <
1.0 nM); dasatinib is currently approved for imatinib-
resistant/intolerant BCR-ABL+ leukemias. At higher
concentrations, dasatinib may inhibit other tyrosine
kinases such as p38, Akt, FAK, and others [18]. This
drug has demonstrated antiproliferative effects on lung
and prostate tumor cell lines [16,17], and its effects on
breast cancer are currently under investigation [19].
Accordingly, we wished to investigate the effects
induced by dasatinib, alone or in combination with RPI-
1, on the TPC-1 cell line, by evaluating cell proliferation,
morphological changes, and phosphorylation reduction.
Additionally, we examined the mechanisms that permit
TPC-1 survival following treatment with the combina-
tion of the two drugs.
Results
Effect of dasatinib on TPC-1 cells
TPC-1 cells, grown in DMEM supplemented with 10%
calf serum, were treated with various concentrations of
dasatinib (100, 300, and 1000 nM) in order to evaluate
Src inhibition and reduction of cell proliferation. As
shown in Figure 1A, the phosphotyrosine profiles of
cells treated with the three different dasatinib concen-
trations did not change. Src phosphorylation at Y416
was reduced at all dasatinib concentrations, and the reg-
ulatory site of SRC (Y527) was switched off while the
autophosphorylation of FAK Y397 appeared to be
enhanced. The proliferation assay (Figure 1B) high-
lighted an association between reduction in proliferation
and increase in dasatinib concentration. In particular,
proliferation was reduced approximately 60%, 65%, and
75% following 72 hours of treatment with 100 nM, 300
nM, and 1000 nM of dasatinib, respectively.
Dasatinib-induced morphological changes
The mesenchymal-like TPC-1 cells normally grow in a
flattened pattern, characterized by many filopodia-like
processes. RPI-1 treatment produced a marked enlarge-
ment and flattening of the cellular morphology and an
increase in cell spreading (Figure 2A) [12]. Moreover, an
increase in actin stress fibers was observed following
RPI-1 treatment. After dasatinib treatment, the cells dis-
played a very different morphology that was character-
ized by a smaller and contracted appearance, and
decreased cell spreading was observed (Figure 2A). As
revealed by confocal microscopy, the actin cytoskeleton
of the cells was modified, creating a more compact cell
body in which the branching actin structures appeared to
be thickened on the cell edges (white arrows Figure 2B).
To further investigate the morphological effects induced
by dasatinib, we probed the protein lysates of the treated
cells for phosphorylation of the cytoskeletal regulatory
proteins p130
CAS, Crk, and paxillin, all of which are sub-
strates of SFKs. We also analyzed the cellular distribution
of the phosphorylated form of paxillin, a focal adhesion
docking protein. After dasatinib treatment we observed
inhibition of Crk phosphorylation and a consistent reduc-
tion in the phosphorylation of p130
CAS and paxillin (Fig-
ure 3A). Since the combined treatment reduced the total
level of p130
CAS protein, we analyzed the phosphorylation
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CAS before and after immunoprecipitation with
anti-p130
CAS antibody, confirming the reduction in pro-
tein phosphorylation (Figure 3A and Additional file 1:
Immunoblot analysis of p130
CAS immunoprecipitation). In
the control and the RPI-1-treated cells, phospho-paxillin
accumulated in well-defined zones highlighting the focal
adhesions of the cells, while after dasatinib and the com-
bined treatments, phospho-paxillin staining was strongly
reduced (Figure 3B).
Dasatinib enhanced RPI-1 effects
Since proliferation was already reduced by 60% in the
presence of 100 nM dasatinib, and the phosphotyrosine
profiles of the cells treated with the three different dasa-
tinib concentrations did not show significant changes,
we used a concentration of 100 nM in all subsequent
experiments.
TPC-1 cells were treated with 40 μM RPI-1, 100 nM
dasatinib, or with both drugs for 24 hours, then the
cells were lysed and extracts were analyzed by immuno-
blotting (Figure 4). The anti-phosphotyrosine profile of
the RPI-1-treated cells differed from that of the dasati-
nib-treated cells, and both presented a specific reduction
in phosphorylated proteins compared with the untreated
cells. Notably, only a few bands were prominent in the
profile of the combined treatment (Figure 4).
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Figure 1 Effect of dasatinib on TPC-1 cells.( A )Left, phosphotyrosine protein profiles of TPC-1 cells treated with various dasatinib
concentrations (100, 300, and 1000 nM). Right, Src and FAK phosphorylation status following dasatinib treatment. Results were normalized by
comparison with beta-actin. (B) Proliferation assay. Left, proliferation curves of TPC-1 cells treated with 100 nM, 300 nM, and 1000 nM dasatinib
after 24, 48, and 72 hours. Right, statistical visualization of the proliferation curves. After 72 hours, the TPC-1 cell proliferation was significantly (p
< 0.001) reduced by 60%, 65%, and 75% after treatment with 100 nM, 300 nM, and 1000 nM dasatinib, respectively.
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liferation by performing a sulforhodamine B assay on
TPC-1 cells treated for 72 hours. After 24 hours the dif-
ference in cell proliferation was not remarkable, but
after 72 hours the reduction in cell proliferation was
consistent (Figure 5). After 72 hours, RPI-1 reduced
TPC-1 cell proliferation by 70%, while dasatinib treat-
ment resulted in a 60% reduction. The combination of
the two drugs reduced proliferation by 83%. No evi-
dences of apoptosis was shown (see Additional file 2:
PARP immunoblot).
Characterization of phosphotyrosine profiles and analysis
of the RPI-1- and dasatinib-sensitive components in TPC-1
cells
In order to dissect alternative pathways involved in
TPC-1 survival, and to better characterize the effects of
the two drugs, we examined the molecular changes
induced by dasatinib and/or RPI-1 treatment by analyz-
ing the proteins that were modulated by the drugs. First,
we identified the most abundant phosphorylated pro-
teins in untreated TPC-1 cells. Protein bands from
untreated TPC-1 lysates were resolved by 4-12% SDS-
PAGE, excised from preparative silver-stained gels, and
processed for MALDI-TOF mass spectrometry (MS)
analysis (Figure 6). The identified proteins are listed in
Table 1.
Among the 38 unique proteins identified by MS, we
selected 11 proteins as representative of the principal
pathways that were analyzed by immunoblotting of anti-
phosphotyrosine (p-Tyr) affinity-purified proteins and
total lysates from untreated and treated TPC-1 cells
(Figure 7). The RPI-1 treatment reduced tyrosine phos-
phorylation of RET, Met proto-oncogene tyrosine kinase
(MET), discoidin (DCDB2), catenin delta-1 (CTND1),
and PLCg. In addition to tyrosine phosphorylation
reduction, the total levels of MET and DCDB2 were
also reduced (Figure 7). Dasatinib enhanced the reduc-
tion in tyrosine phosphorylation of all of the previous
proteins, apart from MET, PLCg and CTND1 (Figure 7).
Dasatinib also reduced the phosphorylation of epidermal
growth factor receptor (EGFR), ephrin type-A receptor 2
(EphA2), and DOK1. Only three of the 11 proteins
remained phosphorylated following the combined treat-
ment (Figure 7). In particular, the tyrosine phosphoryla-
tions of GIT1 and the major vault protein (MVP) were
unmodified as in the single treatments, while EphA2
phosphorylation, which was strongly decreased by dasa-
tinib alone, increased following the combined treatment
(Figure 7). Total level of Focal adhesion kinase 1 (FAK)
phosphorylation appeared unmodified in this experi-
mental setting (Figure 7); of note, dasatinib specifically
inhibited FAK phosphorylation at residues Y576/577,
Y861, and Y925 (Figure 8A).
Residual survival signaling in TPC-1 cells after treatment
with RPI-1 and dasatinib
The combination of the inhibition of RET/PTC by RPI-1
and the inhibition of Src by dasatinib was strongly effec-
tive in reducing proliferation showing high cytostatic
effects. Therefore, we investigated residual survival sig-
naling in TPC-1 cells by immunoblot analysis of selected
survival pathways.
The PI3K/Akt pathway is one of the most important
survival pathways. Our data showed that this pathway is
inhibited by RPI-1 but not by dasatinib (Figure 8A). In
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Figure 2 Morphological effects of drug treatments.( A )O p t i c a l
microscope images of TPC-1 cells before and after drug treatments.
Cell spreading increased following RPI-1 treatment. Dasatinib
treatment changed cellular morphology, characterized by a smaller
appearance. (B) Confocal microscope images of TPC-1 cells before
and after drug treatments. The cells were stained with phalloidin
and DRAQ5. The actin cytoskeletal structure of the cells was
modified following dasatinib treatment; the branching actin
structures appeared to be thickened at the cell edges (white
arrows). Confocal images (512 × 512 pixels) were obtained using a
60× oil immersion lens and were analyzed using ImagePro 6.3
software. Scale bars, 40 μm.
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drugs switched off Akt and Shc as previously demon-
strated [12].
The RPI-1 and dasatinib treatments increased the
amount of ITB1 in a cumulative fashion (Figure 8A/B).
To further verify this result, we performed a FACS analy-
sis with anti-ITB1 antibody, revealing a moderate
increase in ITB1 surface expression (Figure 8B). Immu-
nostaining experiments reflected a qualitative and diffuse
increase in ITB1 expression (see Additional file 3: b1-
integrin immunostaining after drug treatments). Since
the intracellular integrin signal was mediated principally
by activation of FAK, we investigated the phosphoryla-
tion status of this kinase. As expected, the phosphoryla-
tion of FAK drastically changed after treatment with
dasatinib, but not with RPI-1 (Figure 8A). After the inhi-
bition of Src by dasatinib, only the autophosphorylation
site (Y397) of FAK remained phosphorylated.
Since it has been shown that activation of ITB1
enhances STAT3-mediated survival signaling, we
assayed STAT3 activation. The RPI-1 treatment
enhanced the phosphorylated form of STAT3, but dasa-
tinib did not affect it. Regarding the MAP kinase
(MAPK) pathway, we found that ERK1/2 activation was
slightly increased after pharmacological treatment, p38
phosphorylation was reduceda f t e rR P I - 1a n dd a s a t i n i b
treatment and switched off after the combination of the
two drugs and JNK1/2 phosphorylation was reduced
after RPI-1 and the combined treatment (Figure 8A).
Discussion
I nt h ec u r r e n ts t u d yw eh a v ei n v e s t i g a t e dt h em o l e c u l a r
responses of the TPC-1 cell line, spontaneously expres-
sing the RET/PTC1 oncoprotein, toward a combination
of two drugs (RPI-1 against RET/PTC1 and dasatinib
against Src kinase). All data demonstrate that the
DMSO RPI-1
Dasatinib RPI-1 +
Dasatinib
CRK
p130CAS
Lysates
-+- + RPI-1:
DASATINIB: --+ +
IP pTyr
-+- +
--+ +
CRK
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B A
Paxillin
phospho-p130CAS
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IP p130CAS
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DASATINIB:
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Figure 3 Cytoskeletal and focal adhesion changes. (A) Phosphorylation status of the cytoskeletal regulatory proteins p130
CAS, Crk, and paxillin
following drug treatments. Immunoblot analysis indicates down-modulation of cytoskeletal regulatory proteins in terms of protein levels (only
p130
CAS) and tyrosine phosphorylation following dasatinib treatment. (B) Confocal microscope images of TPC-1 cells before and after drug
treatments. Cells were stained for phospho-paxillin (red), actin (green phalloidin) and DRAQ5 to highlight the focal adhesions. In control and RPI-
1-treated cells, phospho-paxillin accumulated in well-defined zones around the focal adhesions, while after dasatinib treatment, phospho-paxillin
disappeared. Confocal images (512 × 512 pixels) were obtained using a 60× oil immersion lens and analyzed using ImagePro 6.3 software. Scale
bars, 10 μm.
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Page 5 of 14combination of the two drugs effectively reduced cell
proliferation (by more than 80%) (Figure 5), significantly
decreased Tyr phosphorylation of almost all phosphoryl-
able proteins (Figure 4), and altered the morphology of
the cells (Figure 2), supporting high cytostatic effects.
The cellular effects of RPI-1 are well known [10-13];
thyroid cell lines treated with this drug strongly main-
tain FAK activation, allowing them to survive. In order
to reduce FAK activation, we treated TPC-1 cells with
dasatinib alone or in combination with RPI-1, achieving
a consistent reduction in FAK phosphorylation (Figure
8). The treated cells showed an overall reduction of
phosphorylated proteins, especially following treatment
with dasatinib and the drug combination. Dasatinib
alone reduced cell proliferation by 60%, while the com-
bination enhanced the reduction up to 80% (Figure 5).
Dasatinib treatment induced morphological changes in
TPC-1 cells, resulting in reduction of the phosphoryla-
tion levels of cytoskeletal regulators such as Crk and
p130
CAS. Crk is an adaptor protein associated with cell
adhesion, and is phosphorylated by SFKs. p130
CAS is a
docking protein that plays a central role in tyrosine-
kinase-based signaling related to cell adhesion, and is
phosphorylated by both FAK and SFKs. Inhibition of
phosphorylation of these proteins causes an altered
maturation of focal complexes to stable focal adhesions,
thus reducing lamellipodium formation, migration, and
invasion [20,21].
Our paxillin staining experiments (Figure 3B) also sug-
gested altered focal adhesion complex formation. Paxil-
lin is a focal adhesion-associated protein that serves as a
docking protein, recruiting signaling molecules to the
focal adhesions. Normally, phosphorylated paxillin loca-
lizes to focal adhesions, permitting staining of these
structures [22]. The expression of a phosphomimetic
paxillin mutant not only increased adhesion assembly
and turnover, but also stimulated the formation of
lamellipodial protrusions [23]. Our findings suggest that,
after dasatinib and combined treatments, the phospho-
paxillin staining was strongly reduced respect to control
cells or cells treated with RPI-1, emphasizing the reduc-
tion in focal adhesions produced by dasatinib treatment.
To more deeply understand the molecular effects of
the drug treatments, and with the aim of dissecting var-
ious pathways involved in TPC-1 proliferation and survi-
val, we analyzed the phosphotyrosine profiles of TPC-1
cells by a proteomic approach, revealing the 38 unique
proteins listed in Table 1. As expected, proteins involved
Figure 4 Phosphotyrosine protein separation of TPC-1 cells before and after drug treatments. (A) anti-p-Tyr immunoblot of equal
amounts of TPC-1 whole-cell extracts from control (0.5% solvent), or cells treated with RPI-1 (40 μM), dasatinib (100 nM), or both, resolved by 4-
12% SDS-PAGE. (B) Effects of RPI-1 and dasatinib treatments (used alone or in combination) on the anti-p-Tyr immunoprecipitates from TPC-1
cells, anti-p-Tyr immunostained and resolved by 3-8% SDS-PAGE.
Caccia et al. Molecular Cancer 2010, 9:278
http://www.molecular-cancer.com/content/9/1/278
Page 6 of 14in RET signaling, such as MET and PLC-g,w e r es u c -
cessfully modulated by RPI-1. Protein kinases including
FAK, receptor tyrosine kinases EGFR and EPHA2, and
the adhesion molecules discoidin and catenin delta-1
were modulated by dasatinib exposure. Our group of 38
proteins also included components of the cytoskeleton:
tropomyosin alpha-1 chain, drebrin, tubulin alpha-1C
chain, and others (Table 1). Eleven of the unique pro-
teins were selected as representatives of the most critical
functional categories, and drug treatment effects were
confirmed by immunoblotting. Eight of these proteins
were modulated by the drugs.
Most of the proteins that are modulated by RPI-1 are
involved in cell survival and proliferation, including
RET, MET, and discoidin. The roles of RET and MET
in cancer development and progression are well-known,
while the implication of discoidin is a recent finding
[24]. In particular, discoidin is involved in cell survival
and migration [24], is overexpressed in highly-metastatic
lung cancer cells [25], and was shown to be a novel tyr-
osine phosphorylation substrate of EGF signaling [26].
On the other hand, in agreement with the inhibition
of FAK and cytoskeletal proteins, dasatinib preferentially
acted on cell adhesion and proliferation by blocking Src
kinase. Src interacts with tyrosine-kinase receptors such
as EGFR and EPHA2, modulating cell proliferation
[27,28], but it is also involved in cell adhesion, as shown
by the modulation of cytoskeletal proteins [20,21]. In
breast cancer, Src interacts with EGFR, enhancing the
activation of mitogenic signaling and promoting cancer
progression [27]. Dasatinib inhibits growth of breast
cancer cells by modulating EGFR signaling [28]. Here
the inactivation of Src reduced the phosphorylation of
EGFR, suggesting an interaction between Src and EGFR
(Figure 7). DOK1, a negative regulator of the Ras-Erk
pathway [29], is another dasatinib-modulated protein
that was shown to interact with a broad range of signal-
ing proteins implicated in the regulation of physiological
responses, including negative regulation of cytokines,
enhanced cell migration, and filopodia extension [30]. In
our study, DOK1 tyrosine phosphorylation did not seem
to be dependent on RET/PTC1 (Figure 7), in contrast
with DOK1 function in medullary thyroid carcinoma,
where its phosphorylation was mediated by mutated
RET [31]. In fact, DOK1 tyrosine phosphorylation was
reduced exclusively after dasatinib treatment (Figure 7).
The behavior of EphA2 phosphorylation was intriguing.
EphA2 is an RTK involved in cancer development and
progression, especially when in its non-phosphorylated
state [32]. Non-phosphorylated EphA2 associates with
FAK and induces the auto-phosphorylation of FAK
Y397 that sustains integrin activation [32]. However,
phosphorylated EphA2 stimulates cell survival and
migration [33]. In our study, EphA2 decreased its phos-
phorylation after dasatinib treatment, but after the com-
bined treatment it conserved its phosphorylation (Figure
7). Thus, we suggest that EphA2 contributes to survival
and migration via FAK in dasatinib-treated cells, but
functions independently of FAK in RPI-1+dasatinib-trea-
ted cells.
Finally, we wished to understand how some cells sur-
vived following the combined treatments, by investigat-
ing survival pathways (Figure 9). The increase in ITB1
after dasatinib treatment suggests that survival may be
mediated by adhesion molecules. Since the intracellular
integrin signal was mediated principally by activation of
FAK, we investigated its phosphorylation status. As
expected, the phosphorylation status of FAK drastically
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by 83%. The interaction was significant (p < 0.001).
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Page 7 of 14changed after treatment with dasatinib, but not with
RPI-1, and the autophosphorylation site of FAK (Y397)
remained phosphorylated (Figure 8A).
PI3K and Shc interact with phospho-Y397 of FAK,
leading to activation of pro-survival proteins such as
Akt. Following treatment with the drug combination,
Akt phosphorylation was completely abrogated while,
after dasatinib alone, Akt activation was not affected,
confirming that Akt activation is driven by RET and not
by the FAK/Src complex (Figures 8, 9) [12,14].
Recent work by Shain et al. [34] has demonstrated
that the fibronectin (FN)-mediated activation of ITB1
enhances the STAT3-mediated survival signaling in
myeloma cells, conferring resistance to apoptosis. RPI-1
treatment enhanced the phosphorylation form of
STAT3, but dasatinib did not affect it (Figure 8).
STAT3 is over-phosphorylated in most cancers, prevent-
ing apoptosis and enhancing proliferation, angiogenesis,
and invasion [35]. Here, STAT3 remained phosphory-
lated after the combination of the two drugs (Figure
8A), probably contributing to cell survival.
The MAPK pathway regulates various cellular activ-
ities, and is deregulated in one-third of all cancers. The
effects of ERK activation vary by cell type, and impact
diverse cellular processes such as proliferation, differen-
tiation, survival, migration, and angiogenesis. p38 nega-
tively regulates cell proliferation and tumorigenesis via
its pro-apoptotic functions. Recent studies have shown
that p38 initiates apoptosis after oxidative stress induced
by activated Ras [36], antagonizing the oncogenic activ-
ity of Ras. p38 activation is essential for the antileuke-
mic effects of dasatinib [37]. JNK can exert dual
functions, which range from the induction of apoptosis
to increased survival by modulating both phosphoryla-
tion and expression of several members of the Bcl-2
protein family [38]. Consequently, we investigated the
MAPKs in our system, finding that ERK1/2 was slightly
increased after pharmacological treatments, while p38
and JNK1/2 was switched off. Transfection of ITB1 into
hepatocarcinoma cells prote c t st h e mf r o ma p o p t o s i s
induced by chemotherapeutic drugs, by activating the
MAPK pathway [39]. ERK activation could be enhanced
as a secondary effect of dasatinib treatment inactivating
the negative regulators DOK1 and p38 [29,36].
To further confirm the hypothesis that survival could
be mediated by ITB1, we combined the pharmacological
treatments with two different integrins inhibitors, a
blocking antibody and a RGD-mimic pentapeptide, but
the inhibition in proliferation was not statistically signif-
icant compared with the inhibition achieved by the
combination of the two drugs (data not shown). A pos-
sible explanation for this behavior could be an abun-
dance of extracellular matrix proteins, such as
fibronectin (data not shown), and adhesion molecules,
for instance SPARC produced by TPC-1 cells, that
could antagonize integrin inhibition. SPARC can modu-
late ERK activation by activating a G-protein coupled
receptor, converging on the integrin signaling pathway
[40], as well as EphA2 receptor known for its impor-
tance in cancer development and its ability to converge
on integrin signaling [32,33].
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Figure 6 Identification of most abundant phosphorylated
proteins. (A) Molecular weight markers. (B) Silver staining of anti-p-
Tyr affinity-purified proteins. Protein extracts were incubated with
anti-p-Tyr agarose-conjugated antibody. Bound proteins were
washed, eluted, and resolved by 4-12% SDS-PAGE. Proteins
identified are indicated in red and listed in Table 1. (C) Gel zone
most abundant in phosphotyrosine proteins.
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Page 8 of 14Conclusions
The current study suggests that RPI-1 and dasatinib act
on two different pathways; dasatinib acts on the FAK/
S r cp a t h w a y ,w h i l eR P I - 1h e a v i l yi m p a i r st h et y r o s i n e
kinase activity of RET. Following a combined treatment,
cell survival pathways appeared to be mediated by
STAT3 and ERK activities resulting from integrin clus-
tering and FAK autophosphorylation (Figure 9) [41,42].
EphA2 may also contribute, at least in part, to integrin
and FAK activation [32,33]. Our data are in agreement
Table 1 Immunoaffinity-purified proteins from untreated TPC-1 cells. The band numbers correspond to that of the gel
in figure 6
Band Score Swiss Prot
accession number
entry name name Coverage MW
1 984.72 P35579 MYH9_HUMAN (C_1) Myosin-9 53 226
79.00 P35580 MYH10_HUMAN (C_1) Myosin-10 33 229
2 31.00 Q9HBL0 TENS1_HUMAN (C_1) Tensin-1 18 186
3 112.96 Q8WWN8 ARAP3_HUMAN (C_1) Arf-GAP, Rho-GAP domain, 18 170
4 48.02 P00533 EGFR_HUMAN (C_1) Epidermal growth factor receptor 26 132
5 215.39 P19174 PLCG1_HUMAN (C_1) 1-phosphatidylinositol-4,5-bisphosphate ... 29 149
6 131.26 Q7L576 CYFP1_HUMAN (C_1) Cytoplasmic FMR1-interacting protein 1 32 145
43.26 Q96F07 CYFP2_HUMAN (C_1) Cytoplasmic FMR1-interacting protein 2 20 148
37.72 P08581 MET_HUMAN (C_1) Hepatocyte growth factor receptor 20 153
7 192.82 Q7L576 CYFP1_HUMAN (C_1) Cytoplasmic FMR1-interacting protein 1 34 145
75.41 P08581 MET_HUMAN (C_1) Hepatocyte growth factor receptor 26 153
54.63 Q69YQ0 CYTSA_HUMAN (C_1) Cytospin-A 28 125
8 34.60 P29597 TYK2_HUMAN (C_1) Non-receptor tyrosine-protein kinase TYK... 17 134
9 74.45 Q9H5V8 CDCP1_HUMAN (C_1) CUB domain-containing protein 1 27 90
10 440.36 Q05397 FAK1_HUMAN (C_1) Focal adhesion kinase 1 46 119
18.63 Q9Y2A7 NCKP1_HUMAN (C_1) Nck-associated protein 1 16 129
24.28 Q9P0K7 RAI14_HUMAN (C_1) Ankycorbin 21 110
11 38.34 Q96PD2 DCBD2_HUMAN (C_1) Discoidin, CUB and LCCL domain-containin... 41 78
29.07 O60716 CTND1_HUMAN (C_1) Catenin delta-1 24 108
23.23 P29317 EPHA2_HUMAN (C_1) Ephrin type-A receptor 2 22 106
12 162.47 Q14764 MVP_HUMAN (C_1) Major vault protein 42 99
17.82 O43707 ACTN4_HUMAN (C_1) Alpha-actinin-4 19 105
13 18.41 O75815 BCAR3_HUMAN (C_1) Breast cancer anti-estrogen resistance p... 18 93
14 58.87 Q9Y2X7 GIT1_HUMAN (C_1) ARF GTPase-activating protein GIT1 37 84
37.01 Q16643 DREB_HUMAN (C_1) Drebrin 34 71
21.79 Q13671 RIN1_HUMAN (C_1) Ras and Rab interactor 1 21 84
15 60.58 Q05655 KPCD_HUMAN (C_1) Protein kinase C delta type 33 78
16 26.25 P11021 GRP78_HUMAN (C_1) 78 kDa glucose-regulated protein 28 70
17 31.38 P11142 HSP7C_HUMAN (C_1) Heat shock cognate 71 kDa protein 29 71
18 46.35 Q9H5V8 CDCP1_HUMAN (C_1) CUB domain-containing protein 1 22 90
19 27.67 Q99704 DOK1_HUMAN (C_1) Docking protein 1 41 52
20 24.69 Q9BQE3 TBA1C_HUMAN (C_1) Tubulin alpha-1C chain 27 50
21 135.18 P60709 ACTB_HUMAN (C_1) Actin, cytoplasmic 1 58 42
135.18 P63261 ACTG_HUMAN (C_1) Actin, cytoplasmic 2 58 42
22 47.94 P09493 TPM1_HUMAN (C_1) Tropomyosin alpha-1 chain 46 33
23 22.66 P19105 MRLC3_HUMAN (C_1) Myosin regulatory light chain MRLC3 57 20
22.53 O14950 MRLC2_HUMAN (C_1) Myosin regulatory light chain MRLC2 57 20
24 47.11 P60660 MYL6_HUMAN (C_1) Myosin light polypeptide 6 56 17
25 23.73 Q9NYM9 BET1L_HUMAN (C_1) BET1-like protein 42 12
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Page 9 of 14with current evidence that cell adhesion-mediated drug
resistance is an important mechanism that may enable
tumor cell survival, bringing resistance to drug-induced
apoptosis [34,43]. In conclusion, dasatinib, in combina-
tion with RPI-1, strongly reduced proliferation, altered
morphology, and changed the phosphorylation protein
profile of TPC-1 cells, implicating ITB1 and EphA2 as
promising therapeutic targets in PTC.
Methods
Cell Culture and Drug Treatment
TPC-1 cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM, GIBCO, Carlsbad, CA, USA) supple-
mented with 10% fetal bovine serum FBS (HyClone
Laboratories, Logan, UT, USA) and 1 mM sodium pyru-
vate. For cell treatment, RPI-1 (8 mM in 100% dimethyl-
sulfoxide, DMSO) and dasatinib (0.2 mM in 100%
DMSO) were directly diluted in cell culture medium to
achieve a final concentration of 40 μMf o rR P I - 1a n d
100 nM for dasatinib. The final solvent concentration
was less than 0.5% for all samples (including controls).
Proliferation assay and immunofluorescence
T h es u l f o r h o d a m i n eB( S R B )p r o l i f e r a t i o na s s a yw a s
used for cell density determination, based on the mea-
surement of cellular protein. SRB was performed in 96
multiwell plates containing cells, seeded at 2000 cell/
cm
2 for 18 h, treated with drugs and fixed with TCA
50% in ddH2O. Fixed cells were stained with 0.4% (wt/
vol) SRB solution for 30 min and rinsed with 1% (vol/
vol) acetic acid. Protein-bound dye was solubilized with
10 mM Tris base (pH 10.5) and the optical density at
550 nm was determined.
For immunofluorescence, cells were grown and treated
on glass chamber slides, fixed in 4% paraformaldehyde
and sucrose, permeabilized with 1% BSA and 0.1% Tri-
ton X-100, saturated with 10% goat serum, and stained
with fluorescent phalloidin (Sigma Aldrich, St. Louis,
Missouri, USA), paxillin (Transduction Laboratory, BD,
Franklin Lake, NJ, USA), and DRAQ5 (Biostatus Lim-
ited, LE, UK) as nuclear markers. Slides were prepared
using ProLong Antifade mounting media (Invitrogen S.r.
l, MI, IT), and imaged with confocal microscopy (Micro-
radiance 2000; Bio-Rad Laboratories) equipped with
argon/krypton (488 nm), HeNe (543 nm), and red laser
diode (638) lasers. Confocal images (512 × 512 pixels)
were obtained using a 60× oil immersion lens and were
analyzed using ImagePro 6.3 software. Reported images
represent extended depth of field from 10-15 frames in
as t a c k( 0 . 5μm step); focus regions were selected for
maximum intensity. The pinhole diameter was regulated
according to the value suggested by the acquisition soft-
ware manufacturer to obtain the maximum resolution
power.
FACS analysis
Cells were seeded on 100-mm tissue culture plates,
incubated for 18 h, then treated with drugs for 24 h and
then washed with PBS, pelleted at 800 rpm for 5 min,
and resuspended at a concentration of 1×10
6 cells/mL
in PBS. After blocking with normal goat serum for 30
minutes, cells were incubated with anti-b1 integrin anti-
body (Clone MAR6) kindly provided by Dr.ssa Tagliabue
E for 1 h at room temperature (RT), pelleted, and
washed three times with PBS to remove excess primary
antibody. Cells were then resuspended in 1 ml of PBS
and incubated with Alexa Fluor(r) 555 (goat anti-mouse
IgG, red) fluorescent labeled secondary antibody for 30
min at RT. After three more washes, cell pellet was
resuspended in PBS and analyzed on a FACsDIVA (Bec-
ton Dickinson).
Figure 7 Validation of identified proteins of interest.
Immunoblot experiments confirming the proteomic selection of
proteins sensitive to RPI-1, dasatinib, or both drugs. Anti-p-Tyr
immunoaffinity-purified proteins from TPC-1 cells, alone or treated
with RPI-1, dasatinib, or both, were resolved by 3-8% SDS-PAGE and
immunoblotted with antibodies specific to MET, discoidin (DCDB2),
EGFR, CTND1, EPHA2, PLCg, DOK1, RET/PTC1, FAK1, MVP, and GIT1.
Normalization of results was obtained by immunoblotting analysis
of beta-actin (ACTB).
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Page 10 of 14Sample preparation and Anti-p-Tyr immunoprecipitation
TPC-1 cells were seeded at 3 × 10
4 cells/cm
2,c u l t u r e d
for 18 h, and exposed to the drugs for 24 h before cell
lysis. Treated and control cells were washed 5 times
with cold phosphate-buffered saline (PBS) containing 0.1
mM sodium orthovanadate, and harvested by scraping
into another 0.5 ml cold PBS before centrifugation at
2 0 0 0×gf o r5m i na t4 ° C .T h es u p e r n a t a n t sw e r ed i s -
carded and the cell pellets were solubilized in cold lysis
buffer containing 50 mM HEPES (pH 7.6), 150 mM
NaCl, 10% glycerol, 1% Triton X-100, 1.5 mM MgCl2,1
mM EGTA, 10 mM Na4P2O7, 100 mM NaF, and 1 mM
sodium orthovanadate in the presence of protease inhibi-
tors (Sigma Aldrich, St. Louis, MO, USA). After 30 min
of incubation with gentle rocking at 4°C, lysates were
cleared by centrifugation. Supernatants were collected
and protein concentrations were determined by Bradford
or BCA assays (Bio-Rad Laboratories Srl, MI, IT).
For anti-p-Tyr immunoprecipitation, samples were
processed as previously described [13].
SDS-PAGE and Immunoblotting
All electrophoresis (SDS-PAGE) and electroblotting experi-
ments were performed with precast polyacrylamide
NuPAGE NOVEX gels (Invitrogen, MI, IT), and with
Hybond-C super nitrocellulose membrane (Amersham
Biosciences, Little Chalfont, UK). For immunoprecipitation
experiments, equal amounts of protein from treated cell
lysates (30 μg) and immunoprecipitates were compared
with non-treated samples on 3-8% precast gels and pro-
cessed as previous described [13]. Proteins were transferred
to nitrocellulose membranes and probed with the
Figure 8 Immunoblot analysis of the survival pathways. (A) Whole-cell lysates, untreated or treated with RPI-1, dasatinib, or both, and
resolved by 4-12% SDS-PAGE, were analyzed by immunoblot experiments with anti-beta1 integrin and anti-phospho-SHC, -Akt, -p38
MAPK, -STAT3,
-ERK1/2, -FAK, and -Src. (B) FACS analysis of TPC-1 before and after treatments showing an increase in b1-integrin surface expression.
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Page 11 of 14appropriate antibodies. Immunoreactive bands were visua-
lized using horseradish peroxidase-linked anti-mouse, anti-
rabbit, or anti-goat antiserum and detected using an
enhanced ECL system (Bio-Rad Laboratories Srl, MI, IT).
In-gel tryptic digestion, MALDI-TOF MS, and peptide mass
fingerprinting
For MALDI-TOF identification, anti-pTyr immunopreci-
pitated proteins were resolved by SDS-PAGE, followed
by silver or colloidal Coomassie staining, according to
standard procedures. Protein bands were excised and
processed as previously described [13]. Briefly, reduced
and carbamylated proteins were in-gel digested with
trypsin (13 ng/μl) for 18 h at 37°C. The peptide mixture
obtained from each band was analyzed by MALDI-TOF
Voyager-DE STR (Applied Biosystems, Framingham,
MA, USA), equipped with a nitrogen laser (337 nm).
The resulting spectra were analyzed with Aldente
software (http://www.expasy.ch/tools/aldente/). Input
was searched according to the following database:
Aldente: UniProtKB/SwissProt; predefined taxon: Mam-
malia; Spectrometer internal error max: 25. Only pro-
teins identified in at least three separate experiments
were considered.
Antibodies and reagents
For immunoprecipitation experiments, anti-phosphotyr-
osine agarose-conjugated PT66 (anti-p-Tyr, Sigma-
Aldrich) was used. For immunoblotting, the following
antibodies were used: anti-p-Tyr 4G10, anti-pShc, anti-
Src (Upstate Biotechnology, Billerica, MA, USA), anti-
discoidin, anti-p130
CAS (Abcam, Inc., Cambridge, MA,
USA), anti-RET (C-19), anti-EGFR (1005), anti-GIT1
(H170), anti-EPHA2 (H175), anti-MET (C12), anti-
PLCg1 (1249), anti-b1-INTEGRIN (N-20), anti-pFAK
(Y576/577, Y861, and Y925), anti-DOK1 (Santa Cruz
Figure 9 Principal pathways involved in TPC-1 cell survival and proliferation. Schematic representation of the principal pathways involved
in TPC-1 cell survival and proliferation. RPI-1 acts on RET/PTC, blocking phosphorylation of the downstream proteins Akt and Shc. Dasatinib acts
on Src, causing changes in focal adhesion proteins and proliferation. After treatment with the combination of RPI-1 and dasatinib, STAT3 and
ERK1/2 remained active, possibly contributing to cell survival.
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Page 12 of 14Biotechnology, Santa Cruz, CA, USA); anti-FAK1, anti-
p130
CAS, anti-paxillin, anti-Crk (Transduction Labora-
tory, BD, Franklin Lake, NJ, USA); anti-beta-actin; anti-
catenin delta-1 (Histo-Line Laboratories, Milan, Italy),
anti-MVP (US Biological, Swampscott, MA, USA),
pp38
MAPK (Y180/182), anti-pSTAT3 (Y705), anti-pAkt
(Ser 473), anti-pSrc (Y527 and Y416), anti-pFAK (Y397),
anti-pPaxillin (Y118), anti-pp130
CAS (Y410) (Cell Signal-
ing Technology, Inc., Boston, MA, USA), anti-pERK1/2
(T183/Y185) (Sigma Aldrich, St. Louis, MO, USA).
Tris, SDS, HEPES, glycerol, Triton X-100, NaCl, and
DMSO were obtained from Sigma Fluka (St. Louis, MO,
USA), silver stain reagents were obtained from Sigma
Aldrich. Coomassie Brilliant Blue G250 reagent stain
was obtained from Bio-Rad.
Statistical analysis
Each experiment was performed at least twice. The sta-
tistical significance of the results was determined using
Student’s t-test. Data were considered significant when
p ≤ 0.05.
Additional material
Additional file 1: Immunoblot analysis of p130
CAS
immunoprecipitation. Whole cell lysates (WCL) of TPC-1 before and
after drug treatments were immunoprecipitated with anti-p130
CAS
antibody (Abcam, Inc., Cambridge, MA, USA). Reductions in both p130
CAS
protein and its phosphorylation in the immunodepleted (ID) samples
were observed. The absence of the p130
CAS protein in the two pre-
cleared (PC) lysates highlighted the specificity of the
immunoprecipitation. The positive control (Ctr +) was the WCL of
untreated cells.
Additional file 2: PARP immunoblot. TPC-1 lysates before and after
drug treatments were stained for the C-terminal domain of the PARP
protein, a marker of cell apoptosis, using an anti-PARP antibody (Cell
Signaling Technology, Inc., Boston, MA, USA). During apoptosis, activated
caspase-3 cleaves PARP protein (116 kDa) into an N-terminal domain (24
kDa) and a C-terminal domain (89 kDa). The total amount of full-length
PARP (116 kDa) was not modified after the treatments, suggesting the
absence of apoptosis.
Additional file 3: b1-integrin immunostaining after drug treatments.
Immunofluorescence microscopy of TPC-1 cells before and after drug
treatments. Cells were stained with anti-b1-integrin antibody (kindly
provided by Tagliabue E) (red) and DRAQ5 (blue). The staining revealed a
qualitative increase in b1-integrin staining, in agreement with the
biochemical and FACS analyses (Figure 8A). Images (512 × 512 pixels)
were obtained using a 60× oil immersion lens and were analyzed using
ImagePro 6.3 software. Scale bars, 10 μm.
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